Categories
Change Password!
Reset Password!
A case series was carried out to evaluate the treatment advantages of botulinum toxin A (Botox) to treat refractory neuropathic pain in both idiopathic and diabetic neuropathy.
In people with idiopathic and diabetic neuropathy, intradermal injection of botulinum toxin A every three months was well-tolerated, and led to effective and sustained improvement in neuropathic pain.
A case series was carried out to evaluate the treatment advantages of botulinum toxin A (Botox) to treat refractory neuropathic pain in both idiopathic and diabetic neuropathy.
Participants diagnosed with neuropathy and who exhibited unsatisfactory responses against three standard neuropathic pain medications were selected. They were given Botox injection (intradermally) every 3 months at 10 locations on the dorsum of each foot. For each procedure, 100U were utilized. To evaluate the pain prior to, during, and post-intervention, the 11-point Likert numeric scale was employed.
Identification of 8 male participants (range of age 47-90 years) was done. One participant had idiopathic neuropathy while the other participants had diabetes. The average neuropathic pain span was found to be 9 years. The duration of the intervention with Botox ranged from three months to twelve years.
Following the first injection, 1 participant withdrew because of discomfort and less improvement than assumed. Substantial enhancement with alleviation of 6.2 points on the Likert scale was observed in other patients. Persistent treatment benefits were witnessed in all the responders.
Intradermal Botox injection has good tolerability and is effective to reduce refractory neuropathic pain in patients having diabetic and idiopathic neuropathy.
Neurology
Use of Botulinum Toxin in the Treatment of Neuropathic Pain: A Case Series (P10-13.009)
XinLi Du et al.
Comments (0)